Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Cash (2020 - 2025)

Historic Change in Cash for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $32.2 million.

  • Xeris Biopharma Holdings' Change in Cash rose 201081.26% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year increase of 15233.85%. This contributed to the annual value of $4.1 million for FY2024, which is 10744.88% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Change in Cash of $32.2 million as of Q3 2025, which was up 201081.26% from $845000.0 recorded in Q2 2025.
  • Xeris Biopharma Holdings' Change in Cash's 5-year high stood at $42.2 million during Q4 2022, with a 5-year trough of -$71.0 million in Q1 2023.
  • Moreover, its 5-year median value for Change in Cash was -$27000.0 (2023), whereas its average is $3.1 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 29447.12% in 2023, then skyrocketed by 575185.19% in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Change in Cash (Quarter) stood at $7.8 million in 2021, then skyrocketed by 442.55% to $42.2 million in 2022, then tumbled by 49.99% to $21.1 million in 2023, then crashed by 41.3% to $12.4 million in 2024, then soared by 160.0% to $32.2 million in 2025.
  • Its last three reported values are $32.2 million in Q3 2025, $845000.0 for Q2 2025, and -$13.2 million during Q1 2025.